Yunu, Inc.

Yunu, Inc. is an innovative company specializing in clinical trial imaging platforms that enhance collaboration and optimize outcomes within the life sciences sector, particularly for oncology-related studies. Yunu, Inc. provides a sophisticated clinical trial imaging platform aimed at improving collaboration in clinical trials.

Founded in Raleigh, US, the company has engaged in a key funding round recently. The founder has a history in the field, although specific previous ventures are not detailed. The company has executed a total of 1 deal, with the most recent deal occurring on April 16, 2025. Yunu specializes in providing a comprehensive clinical trial imaging platform designed to enhance collaboration and optimize outcomes for life science companies and cancer centers.

The core product offering focuses on a unified trial management and patient response solution that streamlines workflows, supports consistent data collection, and facilitates effective communication among radiologists, oncologists, and clinical trial coordinators. Yunu’s technology also extends to patient recruitment, enabling easier onboarding of additional clinical sites, thereby broadening access to diverse patient cohorts. The platform integrates over 30 major response criteria and more than 300 study-specific variants to ensure standardization in trial measurements. Serving an extensive client base, which includes clinical trial sponsors, contract research organizations (CROs), and various cancer centers, Yunu's products are utilized across North America and Europe, making significant inroads into the global healthcare market.

Yunu's revenue model primarily revolves around B2B partnerships with clinical trial sponsors, CROs, and healthcare institutions, allowing them access to the imaging platform and associated services. Transactions typically occur through subscription agreements, where clients pay for ongoing access to the platform and its suite of tools, tailored to meet specific trial requirements. The platform's pricing structure includes tiered subscription plans based on the number of users or clinical sites participating, with additional costs for premium services such as specialized consulting or access to a broader network of trial resources. Key services such as trial management, patient response tracking, and real-time reporting improve operational efficiency for clients, thereby solidifying Yunu's position as a critical partner in the clinical trial process.

In April 2025, Yunu, Inc. raised an undisclosed amount of venture funding led by new investor Spring Mountain Capital. The company will utilize this funding to expand its pharma sponsor and site network to support growth in oncology clinical trials. Future plans include the development of new product features designed to enhance user experience and streamline workflows, with specific features expected to launch in late 2025.

Additionally, Yunu aims to enter new geographic markets, particularly focusing on increasing its presence in the Asia-Pacific region by 2026.